Intracranial Aneurysms in Patients with CREST Syndrome —Two Case Reports—

Total Page:16

File Type:pdf, Size:1020Kb

Intracranial Aneurysms in Patients with CREST Syndrome —Two Case Reports— Neurol Med Chir (Tokyo) 49, 402¿406, 2009 Intracranial Aneurysms in Patients With CREST Syndrome —Two Case Reports— Ryuta NAKAE, Masaru IDEI,KiyoshiKUMANO, Shinji OKITA,andKanjiYAMANE Department of Neurosurgery, Chugoku Rosai Hospital, Kure, Hiroshima Abstract CREST syndrome is a variant of scleroderma characterized by calcinosis, Raynaud's phenomenon, esophageal hypomotility, sclerodactyly, and telangiectasia, and is a collagen vascular disease characterized by inflammation and fibrosis of multiple organs/tissues. Neurological and cerebrovascular abnormalities are uncommon in CREST syndrome. Here, we report two patients with CREST syndrome harboring intracranial aneurysms. A 53-year-old wo- man with a 6-month history of CREST syndrome had multiple intracranial aneurysms that arose from the right mid- dle cerebral artery, the left middle cerebral artery, the choroidal segment of the left internal carotid artery, and the left anterior cerebral artery. A 64-year-old woman with a 2-year history of CREST syndrome had a fusiform aneurysm located on the insular segment of the left middle cerebral artery. These patients were treated surgically and good outcome was achieved in both cases. The pathogenesis of cerebral aneurysms associated with collagen dis- eases, including CREST syndrome, remains unclear. Early treatment of CREST syndrome and other collagen dis- eases may prevent arteritis from progressing to affect the intracranial arteries and thus reduce the occurrence of aneurysms. The prognosis for patients with collagen diseases after rupture of cerebral aneurysm seems to be poor be- cause the multiplicity, atypical morphology, and atypical location of their aneurysms make treatment difficult. Thus, early detection and treatment are important to improve the prognosis. Key words: intracranial aneurysm, CREST syndrome, scleroderma, collagen disease, cerebral arteritis Introduction with transient weakness and numbness of her left upper extremity, as well as dysarthria. Six months earlier, she CREST syndrome is a member of the heterogeneous had noticed change in the color of her fingers and toes fol- scleroderma group of autoimmune diseases that cause lowing exposure to cold and subsequent rewarming (Ray- thickening, hardening, and tightening of the connective naud's phenomenon), and heartburn, dysphagia, and tissue at various sites in the body, and may result in com- swelling of her fingers and toes had occurred from 3 plex disorders. CREST syndrome is characterized by the months before admission. Fiberoptic esophagogastroduo- coexistence of calcinosis, Raynaud's phenomenon, denoscopy revealed multiple proximal esophageal dilata- esophageal hypomotility, sclerodactyly, and telangiecta- tions. Antinuclear antibodies were detected and the an- sia. Usually only three of these five features are considered ticentromere antibody titer was greater than 1:1,280. necessary for the diagnosis of CREST syndrome. Anticen- Based on these clinical and serologic findings, the diagno- tromere antibodies are also frequently detected in patients sis was CREST syndrome. with CREST syndrome.4) Neurological and cerebrovascu- Magnetic resonance (MR) angiography demonstrated lar abnormalities are uncommon in CREST syndrome, un- multiple intracranial aneurysms. Digital subtraction an- like other collagen diseases such as systemic lupus giography identified four aneurysms: An aneurysm 12 mm erythematosus or polyarteritis nodosa.38,56) Only two in diameter arising from the bifurcation of the right mid- patients with CREST syndrome have presented with in- dle cerebral artery (MCA), an aneurysm 16 mm in di- tracranial aneurysm.38,56) ameter arising from the bifurcation of the left MCA, an Here, we describe the clinical features of two patients aneurysm 4 mm in diameter located on the choroidal seg- with CREST syndrome associated with intracranial ment of the left internal carotid artery (ICA), and an aneurysms. aneurysm 2 mm in diameter on the left anterior cerebral artery (ACA) (Fig. 1). The intracranial arteries did not Case Reports demonstrate any irregularities indicative of vasculitis. Surgical treatment was selected with the patient's in- Case 1: A 53-year-old woman was admitted to our hospital formed consent. The first operation treated the aneurysm of the right MCA because we strongly suspected that the Received February 19, 2009; Accepted April 3, 2009 patient's symptoms were caused by embolization of blood 402 Intracranial Aneurysms in Patients With CREST Syndrome 403 clots from this aneurysm. After right frontotemporal Cerebral angiography revealed a broad-necked craniotomy, a large aneurysm located at the bifurcation of aneurysm located on the insular segment of the left MCA the right MCA was identified, and its neck was closed (Fig. 2). The intracranial arteries did not demonstrate any with three clips. A second operation treated two of the irregularities indicative of vasculitis. Surgical treatment threeaneurysmsontheleftside26daysafterthefirst was selected with informed consent. After left frontotem- operation. After left frontotemporal craniotomy, the poral craniotomy, the aneurysm was identified on the in- aneurysms located on the choroidal segment of the left sular segment of the left MCA. Clipping of the aneurysm ICA and at the bifurcation of the left MCA were obliterat- was not feasible because of its fusiform shape, so wrap- ed with one clip and three clips, respectively. Surgical ping with autologous fascia and coating with fibrin glue treatment was not performed for the aneurysm located on were performed. The postoperative course was unevent- the left ACA because of its small size. The postoperative ful, and she was discharged 8 days after surgery without course was uneventful, and she was discharged 20 days af- neurological deficits. ter the second procedure without neurological deficits. Case 2: A 64-year-old woman was referred to our hospital Discussion for evaluation of an intracranial aneurysm that had been found incidentally during a medical check-up. She had a MR angiography has detected increasing numbers of history of CREST syndrome. Her symptoms included Ray- cerebral aneurysms in patients with collagen diseases, naud's phenomenon, arthritic pain, swelling of her fin- with a total of 48 cases reported up to September 2008, gers, and telangiectasia. Antinuclear antibodies were posi- including 25 patients with systemic lupus erythemato- tive and the anticentromere antibody titer was greater sus,1,10,11,14,18–20,22,25,27,30–33,37,42,43,52) 16 patients with polyar- than 1:1,280. The diagnosis of CREST syndrome had been teritis nodosa,2,8,9,24,28,29,35,36,41,44,45,49–51) 5 patients with scl- established 2 years earlier on the basis of the clinical and eroderma,3,17) and 2 patients with CREST syndrome.38,56) laboratoryfindings,andshehadbeentreatedwithoral To determine the specific features of cerebral aneurysm in steroids. patients with collagen diseases, we reviewed the 48 report- ed cases and identified the following four characteristics. First, multiple aneurysms are common in patients with collagen diseases. The incidence of multiple aneurysms (usually two or three lesions) ranges from 5.3% to 33.3%.13,15,21,26,39,47) Eight of 254 (3.1%) patients without collagen diseases had four aneurysms like our Case 1.54) In contrast, 19 of the 48 (39.6%) patients with collagen dis- eases had multiple aneurysms (Table 1), and 9 had five or more aneurysms. Second, there was a high frequency of fusiform Fig. 1. Case 1. A: Right internal carotid angiogram, an- aneurysms. The frequency of fusiform aneurysms is about teroposterior view, showing an aneurysm of the 1% in patients overall.55) However, fusiform aneurysms oc- right middle cerebral artery (MCA) (arrow). B, C: Left internal carotid angiograms, anteroposterior curred in 14 of the 48 (29.2%) reported patients with colla- view (B) and lateral view (C), showing aneurysms gen diseases (Table 1). A total of 102 cases of fusiform of the left MCA (large arrow), left internal carotid aneurysms arising from the MCA have been described, artery (small arrow), and left anterior cerebral ar- and only 20 patients (19.6%) had aneurysms located on the tery (arrowhead). insular segment like our Case 2.5) Third, aneurysms tended to occur on the distal parts of the arteries in patients with collagen diseases. A total of 14 Table 1 Profiles of reported cerebral aneurysms in patients with collagen diseases No. of patients Type of collagen disease Multiple Fusiform Distal aneurysms aneurysm aneurysm SLE 8 6 6 PN 7 6 7 SSc and CREST syndrome 4 2 1 Total (%) 19 (39.6) 14 (29.2) 14 (29.2) Fig. 2 Case 2. Left internal carotid angiogram, 30 CREST: calcinosis, Raynaud's phenomenon, esophageal hy- degrees left anterior oblique view, showing an pomotility, sclerodactyly, and telangiectasia; PN: polyarteri- aneurysm of the left middle cerebral artery (ar- tis nodosa; SLE: systemic lupus erythematosus; SSc: systemic row). sclerosis. Neurol Med Chir (Tokyo) 49, September, 2009 404 R. Nakae et al. Table 2 Glasgow Outcome Scale (GOS) scores in previous cases of collagen disease in patients with rup- tured cerebral aneurysm No. of patients Type of collagen disease GOS GOS GOS scores scores score 4–5 2–3 1 SLE 5 0 12 PN 3 1 7 SSc and CREST syndrome 3 0 0 Total (%) 11 (35.5) 1 (3.2) 19 (61.3) Fig. 3 Case 2. Photomicrographs of the resected middle GOS score of 1 indicates death; 2, persistent vegetative state; meningeal artery branch showing fibrous change 3, severe disability; 4, moderate disability; and 5, good recov- of the adventitia (left, arrows) and the media (right, ery. CREST: calcinosis, Raynaud's phenomenon, esopha- arrows). Elastica van Gieson stain, original mag- geal hypomotility, sclerodactyly, and telangiectasia; PN: nification ×100 (left), ×200 (right). polyarteritis nodosa; SLE: systemic lupus erythematosus; SSc: systemic sclerosis. and capillaries.34) Only two cases of cerebral arteritis af- fecting medium to large vessels have been reported.16,19) A of the 48 (29.2%) patients had distal aneurysms (Table 1), patient with lupus erythematosus had focal necrosis and and 12 (85.7%) of these aneurysms were situated on the infiltration by polymorphonuclear cells in a segment of a posterior vessels.
Recommended publications
  • Visual Recognition of Autoimmune Connective Tissue Diseases
    Seeing the Signs: Visual Recognition of Autoimmune Connective Tissue Diseases Utah Association of Family Practitioners CME Meeting at Snowbird, UT 1:00-1:30 pm, Saturday, February 13, 2016 Snowbird/Alta Rick Sontheimer, M.D. Professor of Dermatology Univ. of Utah School of Medicine Potential Conflicts of Interest 2016 • Consultant • Paid speaker – Centocor (Remicade- – Winthrop (Sanofi) infliximab) • Plaquenil – Genentech (Raptiva- (hydroxychloroquine) efalizumab) – Amgen (etanercept-Enbrel) – Alexion (eculizumab) – Connetics/Stiefel – MediQuest • Royalties Therapeutics – Lippincott, – P&G (ChelaDerm) Williams – Celgene* & Wilkins* – Sanofi/Biogen* – Clearview Health* Partners • 3Gen – Research partner *Active within past 5 years Learning Objectives • Compare and contrast the presenting and Hallmark cutaneous manifestations of lupus erythematosus and dermatomyositis • Compare and contrast the presenting and Hallmark cutaneous manifestations of morphea and systemic sclerosis Distinguishing the Cutaneous Manifestations of LE and DM Skin involvement is 2nd most prevalent clinical manifestation of SLE and 2nd most common presenting clinical manifestation Comprehensive List of Skin Lesions Associated with LE LE-SPECIFIC LE-NONSPECIFIC Cutaneous vascular disease Acute Cutaneous LE Vasculitis Leukocytoclastic Localized ACLE Palpable purpura Urticarial vasculitis Generalized ACLE Periarteritis nodosa-like Ten-like ACLE Vasculopathy Dego's disease-like Subacute Cutaneous LE Atrophy blanche-like Periungual telangiectasia Annular Livedo reticularis
    [Show full text]
  • Genes in Eyecare Geneseyedoc 3 W.M
    Genes in Eyecare geneseyedoc 3 W.M. Lyle and T.D. Williams 15 Mar 04 This information has been gathered from several sources; however, the principal source is V. A. McKusick’s Mendelian Inheritance in Man on CD-ROM. Baltimore, Johns Hopkins University Press, 1998. Other sources include McKusick’s, Mendelian Inheritance in Man. Catalogs of Human Genes and Genetic Disorders. Baltimore. Johns Hopkins University Press 1998 (12th edition). http://www.ncbi.nlm.nih.gov/Omim See also S.P.Daiger, L.S. Sullivan, and B.J.F. Rossiter Ret Net http://www.sph.uth.tmc.edu/Retnet disease.htm/. Also E.I. Traboulsi’s, Genetic Diseases of the Eye, New York, Oxford University Press, 1998. And Genetics in Primary Eyecare and Clinical Medicine by M.R. Seashore and R.S.Wappner, Appleton and Lange 1996. M. Ridley’s book Genome published in 2000 by Perennial provides additional information. Ridley estimates that we have 60,000 to 80,000 genes. See also R.M. Henig’s book The Monk in the Garden: The Lost and Found Genius of Gregor Mendel, published by Houghton Mifflin in 2001 which tells about the Father of Genetics. The 3rd edition of F. H. Roy’s book Ocular Syndromes and Systemic Diseases published by Lippincott Williams & Wilkins in 2002 facilitates differential diagnosis. Additional information is provided in D. Pavan-Langston’s Manual of Ocular Diagnosis and Therapy (5th edition) published by Lippincott Williams & Wilkins in 2002. M.A. Foote wrote Basic Human Genetics for Medical Writers in the AMWA Journal 2002;17:7-17. A compilation such as this might suggest that one gene = one disease.
    [Show full text]
  • Prevalence and Incidence of Rare Diseases: Bibliographic Data
    Number 1 | January 2019 Prevalence and incidence of rare diseases: Bibliographic data Prevalence, incidence or number of published cases listed by diseases (in alphabetical order) www.orpha.net www.orphadata.org If a range of national data is available, the average is Methodology calculated to estimate the worldwide or European prevalence or incidence. When a range of data sources is available, the most Orphanet carries out a systematic survey of literature in recent data source that meets a certain number of quality order to estimate the prevalence and incidence of rare criteria is favoured (registries, meta-analyses, diseases. This study aims to collect new data regarding population-based studies, large cohorts studies). point prevalence, birth prevalence and incidence, and to update already published data according to new For congenital diseases, the prevalence is estimated, so scientific studies or other available data. that: Prevalence = birth prevalence x (patient life This data is presented in the following reports published expectancy/general population life expectancy). biannually: When only incidence data is documented, the prevalence is estimated when possible, so that : • Prevalence, incidence or number of published cases listed by diseases (in alphabetical order); Prevalence = incidence x disease mean duration. • Diseases listed by decreasing prevalence, incidence When neither prevalence nor incidence data is available, or number of published cases; which is the case for very rare diseases, the number of cases or families documented in the medical literature is Data collection provided. A number of different sources are used : Limitations of the study • Registries (RARECARE, EUROCAT, etc) ; The prevalence and incidence data presented in this report are only estimations and cannot be considered to • National/international health institutes and agencies be absolutely correct.
    [Show full text]
  • Eosinophilic Fasciitis (Shulman Syndrome)
    CONTINUING MEDICAL EDUCATION Eosinophilic Fasciitis (Shulman Syndrome) Sueli Carneiro, MD, PhD; Arles Brotas, MD; Fabrício Lamy, MD; Flávia Lisboa, MD; Eduardo Lago, MD; David Azulay, MD; Tulia Cuzzi, MD, PhD; Marcia Ramos-e-Silva, MD, PhD GOAL To understand eosinophilic fasciitis to better manage patients with the condition OBJECTIVES Upon completion of this activity, dermatologists and general practitioners should be able to: 1. Recognize the clinical presentation of eosinophilic fasciitis. 2. Discuss the histologic findings in patients with eosinophilic fasciitis. 3. Differentiate eosinophilic fasciitis from similarly presenting conditions. CME Test on page 215. This article has been peer reviewed and is accredited by the ACCME to provide continuing approved by Michael Fisher, MD, Professor of medical education for physicians. Medicine, Albert Einstein College of Medicine. Albert Einstein College of Medicine designates Review date: March 2005. this educational activity for a maximum of 1 This activity has been planned and implemented category 1 credit toward the AMA Physician’s in accordance with the Essential Areas and Policies Recognition Award. Each physician should of the Accreditation Council for Continuing Medical claim only that credit that he/she actually spent Education through the joint sponsorship of Albert in the activity. Einstein College of Medicine and Quadrant This activity has been planned and produced in HealthCom, Inc. Albert Einstein College of Medicine accordance with ACCME Essentials. Drs. Carneiro, Brotas, Lamy, Lisboa, Lago, Azulay, Cuzzi, and Ramos-e-Silva report no conflict of interest. The authors report no discussion of off-label use. Dr. Fisher reports no conflict of interest. We present a case of eosinophilic fasciitis, or Shulman syndrome apart from all other sclero- Shulman syndrome, in a 35-year-old man and dermiform states.
    [Show full text]
  • 21362 Arthritis Australia a to Z List
    ARTHRITISINFORMATION SHEET Here is the A to Z of arthritis! A D Goodpasture’s syndrome Achilles tendonitis Degenerative joint disease Gout Achondroplasia Dermatomyositis Granulomatous arteritis Acromegalic arthropathy Diabetic finger sclerosis Adhesive capsulitis Diffuse idiopathic skeletal H Adult onset Still’s disease hyperostosis (DISH) Hemarthrosis Ankylosing spondylitis Discitis Hemochromatosis Anserine bursitis Discoid lupus erythematosus Henoch-Schonlein purpura Avascular necrosis Drug-induced lupus Hepatitis B surface antigen disease Duchenne’s muscular dystrophy Hip dysplasia B Dupuytren’s contracture Hurler syndrome Behcet’s syndrome Hypermobility syndrome Bicipital tendonitis E Hypersensitivity vasculitis Blount’s disease Ehlers-Danlos syndrome Hypertrophic osteoarthropathy Brucellar spondylitis Enteropathic arthritis Bursitis Epicondylitis I Erosive inflammatory osteoarthritis Immune complex disease C Exercise-induced compartment Impingement syndrome Calcaneal bursitis syndrome Calcium pyrophosphate dehydrate J (CPPD) F Jaccoud’s arthropathy Crystal deposition disease Fabry’s disease Juvenile ankylosing spondylitis Caplan’s syndrome Familial Mediterranean fever Juvenile dermatomyositis Carpal tunnel syndrome Farber’s lipogranulomatosis Juvenile rheumatoid arthritis Chondrocalcinosis Felty’s syndrome Chondromalacia patellae Fibromyalgia K Chronic synovitis Fifth’s disease Kawasaki disease Chronic recurrent multifocal Flat feet Kienbock’s disease osteomyelitis Foreign body synovitis Churg-Strauss syndrome Freiberg’s disease
    [Show full text]
  • Clinical Aspects of Systemic Sclerosis (Scleroderma)
    854 Annals of the Rheumatic Diseases 1991; So: 854-861 Clinical aspects of systemic sclerosis (scleroderma) Richard M Silver Systemic sclerosis (scleroderma) is a disease of course of the illness, one hopes to identify unknown cause, the hallmark of which is patients at greater or lesser risk of developing induration of the skin. Although long regarded certain visceral complications, as well as provide as a bland fibrotic process, there is now ample a more homogeneous group of patients for evidence of an active inflammatory process studies of the pathogenesis, clinical manifesta- underlying thepathogenesisofsystemic sclerosis. tions, and treatment. In addition, microvascular disease and immuno- logical abnormalities are present in most cases. It remains to be determined just how the Clinical features immunological and microvascular changes RAYNAUD'S PHENOMENON relate to the overproduction of collagen and Raynaud's phenomenon refers to episodic digital other matrix elements by the fibroblast, but ischaemia provoked by cold or emotion. recent data suggest that products of the immune Although classically described as triphasic- response may directly affect fibroblasts and that is, pallor followed by cyanosis, and then endothelial cells in vitro. hyperaemia accompanied by numbness and This review will focus on recent advances in pain, such a three colour response does not the understanding of several clinical aspects of occur universally. Pallor seems to be the most systemic sclerosis. The reader is referred to reliable sign and hyperaemia the least reliable several recent chapters and textbooks for a more sign in subjects who lack the classic triphasic extensive review. 1-3 response. A recently described questionnaire and colour chart may facilitate the diagnosis of Raynaud's phenomenon.6 Classification Establishment of the presence or absence of Scleroderma may exist as a localised or a Raynaud's phenomenon is important when systemic disease process.
    [Show full text]
  • Hepatic Manifestations of Autoimmune Rheumatic Diseases ANNALS of GASTROENTEROLOGY 2005, 18(3):309-324309
    Hepatic manifestations of autoimmune rheumatic diseases ANNALS OF GASTROENTEROLOGY 2005, 18(3):309-324309 Review Hepatic manifestations of autoimmune rheumatic diseases Aspasia Soultati, S. Dourakis SUMMARY the association between primary autoimmune rheumatolog- ic disease and associated hepatic abnormalities and the Autoimmune rheumatic diseases including Systemic Lu- pharmaceutical interventions that are related to liver dam- pus Erythematosus, Rheumatoid Arthritis, Sjogrens syn- age are presented. drome, Myositis, Antiphospholipid Syndrome, Behcets syndrome, Scleroderma and Vasculitides have been associ- Key words: Connective Tissue Disease, Systemic Lupus Ery- ated with hepatic injury by virtue of multisystem immune thematosus, Rheumatoid Arthritis, Sjogrens syndrome, and inflammatory involvement. Liver involvement preva- Myositis, Giant-Cell Arteritis, Antiphospholipid Syndrome, lence, significance and specific hepatic pathology vary. Af- Behcets syndrome, Scleroderma, Vasculitis, Steatosis, Nod- ter careful exclusion of potentially hepatotoxic drugs or co- ular Regenerative Hyperplasia, portal hypertension, Autoim- incident viral hepatitis the question remains whether liver mune Hepatitis, Primary Biliary Cirrhosis, Primary Scleros- involvement emerges as a manifestation of generalized con- ing Cholangitis nective tissue disease or it reflects an underlying primary liver disease sharing an immunological mechanism. Com- 1. Introduction monly recognised features include mild elevation of liver A variety of autoimmune rheumatic diseases
    [Show full text]
  • Skin Manifestations of Systemic Disease
    THEME WEIRD SKIN STUFF Adriene Lee BSc(Med), MBBS(Hons), FACD, is visiting dermatologist, St Vincent's Hospital and Monash Medical Centre, and Lecturer, Department of General Practice, Monash University, Victoria. [email protected] Skin manifestations of systemic disease Dermatologic complaints are a common reason for Background presentation to a general practitioner. In such cases, one needs Dermatologic complaints are a common reason for presentation to determine if the complaint may be a manifestation of a more to a general practitioner. In some cases, one needs to determine serious underlying systemic disease. Disorders of the every if the complaint may be a manifestation of a more serious underlying systemic disease. organ system may cause skin symptoms and signs, some of which are due to treatment of these conditions. It is beyond the Objective scope of this review to cover all potential skin manifestations of This article aims to highlight common dermatologic systemic disease. This article highlights the more common, presentations where further assessment is needed to exclude classic and important manifestations in three different groups: an underlying systemic disease, to discuss classic cutaneous features of specific systemic diseases, and to outline rare • ‘When to look further’ – where dermatologic presentations cutaneous paraneoplastic syndromes. require further assessment to exclude underlying systemic disease, and guide appropriate management Discussion • ‘What to look for’ – where certain systemic diseases have Skin manifestations of systemic disease are wide, varied, classic cutaneous findings specific and nonspecific. Generalised pruritus and cutaneous • ‘What not to miss’ – where specific cutaneous signs might be vasculitis are more common cutaneous presentations where an underlying systemic disease may be present and will the initial presentation of an underlying malignancy.
    [Show full text]
  • Systemic Sclerosis/Scleroderma: a Treatable Multisystem Disease
    Systemic Sclerosis/Scleroderma: A Treatable Multisystem Disease MONIQUE HINCHCLIFF, MD, and JOHN VARGA, MD Northwestern University, Feinberg School of Medicine, Chicago, Illinois Systemic sclerosis (systemic scleroderma) is a chronic connective tissue disease of unknown etiology that causes wide- spread microvascular damage and excessive deposition of collagen in the skin and internal organs. Raynaud phenome- non and scleroderma (hardening of the skin) are hallmarks of the disease. The typical patient is a young or middle-age woman with a history of Raynaud phenomenon who presents with skin induration and internal organ dysfunction. Clinical evaluation and laboratory testing, along with pulmonary function testing, Doppler echocardiography, and high-resolution computed tomography of the chest, establish the diagnosis and detect visceral involvement. Patients with systemic sclerosis can be classified into two distinct clinical subsets with different patterns of skin and internal organ involvement, autoantibody production, and survival. Prognosis is determined by the degree of internal organ involvement. Although no disease-modifying therapy has been proven effective, complications of systemic sclerosis are treatable, and interventions for organ-specific manifestations have improved substantially. Medications (e.g., cal- cium channel blockers and angiotensin-II receptor blockers for Raynaud phenomenon, appropriate treatments for gastroesophageal reflux disease) and lifestyle modifications can help prevent complications, such as digital ulcers and Barrett esophagus. Endothelin-1 receptor blockers and phosphodiesterase-5 inhibitors improve pulmonary arte- rial hypertension. The risk of renal damage from scleroderma renal crisis can be lessened by early detection, prompt initiation of angiotensin-converting enzyme inhibitor therapy, and avoidance of high-dose corticosteroids. Optimal patient care includes an integrated, multidisciplinary approach to promptly and effectively recognize, evaluate, and manage complications and limit end-organ dysfunction.
    [Show full text]
  • Mixed Connective Tissue Disease • Prognosis • Prophylaxis • Abbreviations • Diagnostic and Treatment Guidelines
    Systemic connective tissue diseases LECTURE IN INTERNAL MEDICINE FOR V COURSE STUDENTS M. Yabluchansky, L. Bogun, L. Martymianova, O. Bychkova, N. Lysenko, M. Brynza V.N. Karazin National University Medical School’ Internal Medicine Dept. Plan of the Lecture Systemic connective tissue diseases • Definition • Classification • Mechanisms • Selected systemic connective tissue diseases • Marfan syndrome • Systemic lupus erythematosus • Scleroderma • Sjögren syndrome • Mixed connective tissue disease • Prognosis • Prophylaxis • Abbreviations • Diagnostic and treatment guidelines https://s-media-cache-ak0.pinimg.com/236x/01/00/a6/0100a6ca7539b8c4f99a369a2bb1c3a8.jpg Definition • Systemic connective tissue diseases (systemic autoimmune diseases, collagen diseases, collagen vascular diseases , SCTD) refer to a group of chronic autoimmune inflammatory disorders involving the protein-rich connective tissue that supports organs and other parts of the body, first of all the joints, muscles, skin, and other organs and organ systems, including the eyes, heart, lungs, kidneys, gastrointestinal tract, and blood vessels. • There are more than 200 disorders that affect the connective tissue. http://www.webmd.com/a-to-z-guides/connective-tissue-disease Classification Heritable SCTD • Marfan syndrome • Peyronie's disease • Ehlers-Danlos syndrome • Osteogenesis imperfecta • Stickler syndrome • Alport syndrome • Congenital contractural arachnodactyly • Loeys–Dietz syndrome https://en.wikipedia.org/wiki/Connective_tissue_disease Classification Acquired SCTD
    [Show full text]
  • Nutritional Implications of GI-Related Scleroderma
    NUTRITION ISSUES IN GASTROENTEROLOGY, SERIES #148 Carol Rees Parrish, M.S., R.D., Series Editor Nutritional Implications of GI-Related Scleroderma Soumya Chatterjee Scleroderma (SSc) is an autoimmune disease characterized by progressive fibrosis of skin and various internal organs, including the lungs, heart, kidneys, and the gastrointestinal (GI) tract. Second only to skin disease, GI tract involvement is the next most common manifestation of SSc. Any part of the GI tract may be affected, leading to considerable impairment of quality of life. When GI involvement is extensive, severe malnutrition can occur and it can even result in death in about 20% of patients. Early recognition and management may alter the long-term outcome. Effective collaboration with gastroenterologists in the evaluation and management of SSc in a multispecialty partnership model has the potential to produce better outcomes and improve survival in these patients. This article discusses the nutritional implications and current evidence-based management recommendations for the wide range of GI manifestations in SSc. INTRODUCTION cleroderma, or systemic sclerosis (SSc), is originally coined (Gr., ‘skleros’ = thickening, ‘dermos’ an autoimmune disease of unclear etiology, = skin). There are two main subtypes of SSc, based on Scharacterized by progressive fibrosis of skin the extent of skin hardening: and various internal organs, an ongoing occlusive • limited SSc (lcSSc, formerly CREST syndrome) microvasculopathy, and abnormalities of the immune only involving the distal extremities (beyond system. There is wide variability in the prevalence of elbows and knees) and face. SSc worldwide. In the United States, about 250 cases per million Americans are afflicted with this disease. • diffuse SSc (dcSSc), where skin tightening is Progressive skin thickening is an integral part of the widespread, including the trunk and proximal disease, explaining how the term ‘scleroderma’ was extremities.
    [Show full text]
  • Systemic Sclerosis Presenting As CREST Syndrome: a Case Report and Review
    JOURNAL OF ERITREAN MEDICAL ASSOCIATION JEMA Systemic sclerosis presenting as CREST syndrome: A case report and review Amanuel Habtemichael1, Asmerom Tesfamariam1, Daniel Tekie1, Wienishet, MD2 Institutional affiliation: 1 Orotta School of Medicine 2 Orotta National Medical Surgical Referral Hospital Corresponding author: Amanuel Habtemichael Orotta School of Medicine P.O.Box 10549, Asmara, Eritrea : Email: [email protected] Abstract Systemic sclerosis (SSc) is a chronic multisystem disorder of unknown etiology, characterized by diffuse fibrosis; degenerative changes; and vascular abnormalities in the skin (scleroderma), articular structures, and internal organs especially the esophagus, GI tract, lung, heart, and kidney. We report the case of a 31 years old female patient who came to the ED with complications of SSc after has been diagnosed with a limited cutaneous scleroderma. This case illustrates the varied multisystem presentation of SSc. Introduction revealed enlargement of right atrium and ventricle, and tricuspid regurgitation without valvular fibrosis. Systemic sclerosis (systemic scleroderma) is a Along with full investigations and management diagnose chronic connective tissue disease of unknown etiology was established as limited cutaneous scleroderma with that causes widespread microvascular damage and RHF secondary to pulmonary arterial hypertension. She excessive deposition of collagen in the skin and was discharged home with lasix 40 mg PO daily, digoxin internal organs. 1 The degree and rate of skin and 0.125 mg PO daily and prendisolone 5 mg in tapering dose. internal organ involvement vary among patients. SSc She had been following at the dermatology, cardiac and has a worldwide distribution and affects all races. The infectious clinics of the hospital with the periodically given prevalence of scleroderma is estimated to be between medications.
    [Show full text]